Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1613 1632 1635 1636 1638 1642
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18553357 | Specific Oligonucleotide-Programmed Readthrough of Nonsense Codons | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 17921027 | IMPROVED CAS 12A/NLS MEDIATED THERAPEUTIC GENE EDITING PLATFORMS | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 18280092 | RNAI CONJUGATES AND USES THEREOF | Non-Final OA | NOVO NORDISK A/S |
| 18752501 | MULTI-VECTOR RECOMBINASE MEDIATED CASSETTE EXCHANGE | Non-Final OA | Genentech, Inc. |
| 18957216 | COMPOSITIONS AND METHODS FOR EFFICIENT IN VIVO DELIVERY | Non-Final OA | President and Fellows of Harvard College |
| 18957270 | COMPOSITIONS AND METHODS FOR EFFICIENT IN VIVO DELIVERY | Non-Final OA | President and Fellows of Harvard College |
| 18715578 | COMPOSITIONS AND METHODS FOR EFFICIENT IN VIVO DELIVERY | Non-Final OA | President and Fellows of Harvard College |
| 18334074 | TYPE VI CRISPR ORTHOLOGS AND SYSTEMS | Final Rejection | President and Fellows of Harvard College |
| 17779953 | SYSTEMS AND METHODS FOR EVALUATING CAS9-INDEPENDENT OFF-TARGET EDITING OF NUCLEIC ACIDS | Non-Final OA | President and Fellows of Harvard College |
| 18246408 | CORONAVIRUS REPLICONS FOR ANTIVIRAL SCREENING AND TESTING | Final Rejection | MERCK SHARP & DOHME LLC |
| 17783938 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | Final Rejection | Merck Sharp & Dohme LLC |
| 18798198 | Treatment Of Hyperglycemia With Solute Carrier Family 39 Member 5 (SLC39A5) Inhibitors | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18267144 | METHOD FOR PROGRAMMABLE CONTROL OF RNA TRANSCRIPT LEVELS WITH AUTOREGULATED CRISPR-CAS13D | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18045873 | AAV VARIANTS WITH HOST ANTIBODY ESCAPE CAPABILITIES AND ALTERED TISSUE TARGETING PROPERTIES | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18048238 | DISCOVERY AND ENGINEERING OF INTEGRASES FOR HIGH-EFFICIENCY GENE INTEGRATION | Non-Final OA | Massachusetts Institute of Technology |
| 18265226 | COMPOSITIONS TARGETING WDR37 AND METHODS OF USE THEREOF | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18029717 | METHOD AND AGENT FOR TREATING/PREVENTING NEURODEGENERATIVE DISEASE AND ASSOCIATED NEUROINFLAMMATION AND FOR EVALUATING PUTATIVE PROPHYLACTICS/THERAPEUTICS FOR TREATING/PREVENTING NEURODEGENERATIVE DISEASE AND NEUROINFLAMMATION | Non-Final OA | THE TRUSTEES OF DARTMOUTH COLLEGE |
| 18014692 | USE OF SATIVENE, AND RECOMBINANT BIOCONTROL FUNGUS AND MUSCARDINE CADAVER AND USE THEREOF | Non-Final OA | ZHEJIANG UNIVERSITY |
| 18547102 | FOLLICULIN iRNA COMPOSITIONS AND METHODS THEREOF | Non-Final OA | ALNYLAM PHARMACEUTICALS, INC. |
| 18262438 | COMPOUNDS AND METHODS FOR REDUCING DUX4 EXPRESSION | Non-Final OA | Ionis Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy